Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients

The University of Texas System (UT)

Status: Completed

Conditions: Type 2 Diabetes Mellitus

Treatments: Drug: Canagliflozin; Drug: Liraglutide

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT02324842

HSC20140322H (Other Identifier)

28431754DIA4009

Details and patient eligibility

About

Specific Aim 1.To examine whether the combination of liraglutide plus canagliflozin can prevent the increase in Hepatic Glucose Production (HGP) following institution of canagliflozin therapy and produce an additive or even synergistic effect to lower the plasma glucose concentration and A1c.

Specific Aim 2: To examine whether combination therapy with liraglutide plus canagliflozin can produce an additive, or even synergistic, effect to promote weight loss and reduction in hepatic and visceral fat content.

Specific Aim 3. To examine whether combination therapy with liraglutide plus canagliflozin can produce an additive or even synergistic effect to reduce systolic/diastolic blood pressure and 24-hour integrated blood pressure.

Full description

Specific Aim 1.To examine whether the combination of liraglutide plus canagliflozin can prevent the increase in HGP following institution of canagliflozin therapy and produce an additive or even synergistic effect to lower the plasma glucose concentration and A1c. We will examine this hypothesis by comparing the effect of administration of liraglutide alone, canagliflozin alone, and the combination of liraglutide plus canagliflozin on:(i) the rate of HGP; (ii) decrease in fasting plasma glucose concentration; (iii) counter-regulatory hormone response and (iv) A1c. We anticipate that the addition of liraglutide to canagliflozin will prevent the increase in plasma glucagon concentration, augment insulin secretion, and blunt/block the increase in HGP in response to canagliflozin, resulting in a greater decrease in fasting plasma glucose concentration and A1c than observed with each therapy alone.

Specific Aim 2: To examine whether combination therapy with liraglutide plus canagliflozin can produce an additive, or even synergistic, effect to promote weight loss and reduction in hepatic and visceral fat content.

Specific Aim 3. To examine whether combination therapy with liraglutide plus canagliflozin can produce an additive or even synergistic effect to reduce systolic/diastolic blood pressure and 24-hour integrated blood pressure.

Enrollment: 45 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female subjects between the ages of 18-70
• Subjects with Type 2 Diabetes Mellitus (T2DM)
• Drug naïve or on stable dose (more than 3 months) of metformin with or without sulfonylurea
• Have an HbA1c levels ≥7.0% and <10.0%
• Stable weight (± 3 lbs) over the preceding 3 months

Exclusion criteria

• Subjects taking drugs known to affect glucose metabolism (other than metformin) will be excluded.
• Individuals with evidence of proliferative diabetic retinopathy or plasma creatinine >1.4 females or >1.5 males or estimated Glomerular Filtration Rate (eGFR)< 60 ml/min.172m2 will be excluded
• Unstable body weight (change of greater than ±3 lbs over the preceding 3 months)
• Participates in excessively heavy exercise program

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

45 participants in 3 patient groups

Canagliflozin

Active Comparator group

Description:

canagliflozin (film-coated tablet), 100 mg/day, increased to 300 mg/day after week two if tolerated without side effects

Treatment:

Drug: Canagliflozin

liraglutide

Active Comparator group

Description:

liraglutide, 1.2 mg/day, increased to 1.8 mg/day after week two if tolerated without side effects

Treatment:

Drug: Liraglutide

canagliflozin plus liraglutide

Active Comparator group

Description:

canagliflozin, 100 mg/day, plus liraglutide, 1.2 mg/day, increased to 300 mg/day and 1.8 mg/day, respectively at week two, if tolerated without side effects

Treatment:

Drug: Liraglutide

Drug: Canagliflozin